

1 Title:

2 Translation, reliability, and validity of Amharic versions of the Pelvic Floor Distress Inventory
3 (PFDI-20) and Pelvic Floor Impact Questionnaire (PFIQ-7)

4

5 Tadesse Belayneh Melkie^{1*}, Zelalem Mengistu Gashaw², Zelalem Ayichew Workineh², Tamiru
6 Minwuye Andargie², Tibebe Zena Debele³ and Solomon Gedlu Nigatu⁴.

7

8 * **Corresponding author:** Tadesse Belayneh Melkie.

9 E-mail: tadbel20@gmail.com;  <https://orcid.org/0000-0003-2578-4203>

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25 **Affiliations**

- 26 1. Tadesse Belayneh Melkie. Department of Anesthesia, School of Medicine, College of
27 Medicine and Health Sciences, University of Gondar, Ethiopia.
- 28 2. Zelalem Mengistu Gashaw. Department of Obstetrics and Gynecology, School of
29 Medicine, College of Medicine and Health Science, University of Gondar, Ethiopia.
- 30 3. Zelalem Ayichew Workineh. Department of Obstetrics and Gynecology, School of
31 Medicine, College of Medicine and Health Science, University of Gondar, Ethiopia.
- 32 4. Tamiru Minwuye Andargie. Department of Obstetrics and Gynecology, School of
33 Medicine, College of Medicine and Health Science, University of Gondar, Ethiopia.
- 34 5. Tibebe Zena Debele. Department of Clinical Midwifery, School of Midwifery, College of
35 Medicine and Health Sciences, University of Gondar, Ethiopia
- 36 6. Solomon Gedlu Nigatu. Department of Epidemiology and Biostatistics, Institute of Public
37 Health, College of Medicine and Health Sciences, University of Gondar, Ethiopia

38

39

40

41

42

43

44

45

46

47

48 **Abstract**

49 **Purpose**

50 Pelvic Floor Disorders (PFDs) affects many women and have a significant impact on their
51 quality of life. Pelvic Floor Impact Questionnaire (PFIQ-7) and Pelvic Floor Distress Inventory
52 (PFDI-20) help to assess PFDs; however, both are not culturally translated into the Amharic-
53 language. Hence, we aimed to translate the English versions of short forms of the PFDI-20 and
54 PFIQ-7 into Amharic-language and evaluate their psychometric properties in Amharic-speaking
55 Ethiopian women with symptomatic PFDs.

56 **Methods**

57 The PFDI-20 and PFIQ-7 were translated into Amharic language using standard procedures. The
58 Amharic versions were completed by 197 patients (response rate 92%) with PFDs from
59 University of Gondar specialized and comprehensive Hospital. Internal consistency and test-
60 retest reliability were examined through Cronbach's alpha and Intraclass correlation coefficients
61 (ICC). A relative criterion standard, POP-SS-7 score, was correlated with total PFDI-20 and
62 subscale POPDI-6 scores (spearman's rank order correlation (SCC). Construct validity was
63 evaluated by known group validity using the Mann–Whitney U test.

64 **Results**

65 Both instruments were successfully translated and adapted with an excellent content validity (>
66 0.90). The Amharic versions of the PFDI-20 and PFIQ-7 showed excellent internal consistency
67 and test-retest reliability in both summary and subscales (Cronbach's alpha: 0.92 for PFDI-20
68 and 0.91 for PFIQ-7; and ICC: 0.97 for PFDI-20 and 0.86 for PFIQ-7). Criterion validity was
69 good for POPDI-6 (SCC = 0.71; $p < 0.001$). Moreover, construct validity was acceptable,
70 showing significant differences among groups of PFDs in the PFDI-20 and PFIQ-7 scores
71 (Mann–Whitney U Test; $p < 0.001$).

72 **Conclusions**

73 The Amharic versions of the PFDI-20 and PFIQ-7 are comprehensible, reliable, valid, and
74 feasible in Ethiopian Amharic-speaking women with PFDs to evaluate symptoms and its impact
75 during research and clinical practice. However, further studies are needed to evaluate the
76 responsiveness.

77 **Keywords:** Amharic Validation. Ethiopian. Pelvic Organ Prolapse. Pelvic Floor Dysfunction.
78 Reliability. Validity.

79 Introduction

80 Pelvic floor disorders (PFDs), one of the chronic women's health problems, is a condition that
81 comprises pelvic organ prolapse (POP), urinary incontinence (UI), and fecal incontinence (FI)
82 (1). Globally PFDs are common debilitating health problem that affects several women (2). In
83 low and middle-income countries (LMICs), the prevalence of one or more PFDs has been
84 reported to be 25% (3). In Ethiopia, although many women with PFDs do not disclose their
85 health problem (4), one-fifth of women suffers from at least one type of PFDs (5).

86 Although mortality is rare, PFDs negatively impact women's health-related quality of life
87 (HRQoL) with physical, psychological, sexual, and social implications (2, 3, 6, 7). The severity
88 of symptoms and their impact on QoL are important parameters in the management and follow-
89 up of women with PFDs (8, 9). Hence, in urogynecology, the use of patient-reported outcomes
90 (PRO) for outcome measures is recommended (10). PROs are measures of health reported
91 directly by patients without amendment or interpretation by clinicians or anyone else (11).

92 In women with PFDs, several PRO measures have been developed for measuring symptoms
93 burden, functional status and QoL (12). The Pelvic Floor Distress Inventory (PFDI-20) and the
94 Pelvic Floor Impact Questionnaire (PFIQ-7) are the two most frequent, generic,
95 psychometrically valid, and reliable PROs for measuring the extent to which PFDs affect
96 HRQoL (13, 14). PFDI investigates the range of PFD symptoms and the inconvenience they
97 cause, while PFIQ covers the impact on daily life. Both instruments are widely used and have
98 been translated into several different countries and languages (15-18). In Ethiopia, PFDI-20 and
99 PFIQ-7 have also been validated in Tigrigna (19). However, they are not adapted and validated
100 for Amharic-speaking Ethiopian women. In contrast, there are POP-specific Amharic versions
101 (the Prolapse Symptom Score (POP-SS) and Prolapse Quality of Life (P-QoL-20)) that measure
102 POP symptoms, their severity, and their impact on HRQoL (20, 21). Amharic is the working
103 language of federal government in Ethiopia with millions of native and second-language
104 speakers. It is spoken as the first language in the region where the study was conducted (22, 23).
105 It is clear that before the use of any PROs in a different language, they should always be adapted
106 and their psychometric characteristics tested in the new language (24). This helps to reduce
107 flawed research conclusions and allows comparison of international studies (25). Therefore, we

108 aimed to translate the PFDI-20 and PFIQ-7 into the Amharic language and evaluate their
109 measurement properties (reliability and validity).

110 **Materials and methods**

111 The study was conducted in two phases: phase 1 included the translation and adaptation of the
112 instruments into the Amharic language and phase 2 comprised the evaluation of their
113 psychometric properties. The University of Gondar Institutional Ethics Review Committee
114 approved the study protocol (Registration number: V/P/RCS/05/540/2020; December 15, 2020).
115 Also, translation permission was obtained from the original instrument developers. All
116 participants were informed and gave their written consent before participating in the study.

117 **Measurement instruments**

118 The PFDI consists of 20 questions and contains three subscales: Pelvic Organ Prolapse Distress
119 Inventory (POPDI-6) with six questions about the inconvenience of the prolapse, Colorectal-
120 Anal Distress Inventory (CRADI-8) with eight questions concerning difficulties of defecation,
121 and the Urinary Distress Inventory (UDI-6) with six questions about difficulties in urination.
122 Response options for rating distress associated with each symptom ranged from 0 (“no” as in no
123 symptoms) to 1 (“not at all” as in symptoms are present but not bothered at all) to 4 (“quite a bit”
124 as in symptoms are present and quite a bit bothered). The mean score of answered items is
125 multiplied by 25 to obtain the scale score (range 0–100) on each scale. Summary scores are
126 calculated by adding up the scale scores (range 0–300). Higher scores indicate more symptom
127 distress (13, 14).

128 The PFIQ consists of 21 items that measures the impact of bladder, bowel, and vaginal
129 symptoms on daily activity, social/relationships, and emotional health. It has three scales: the
130 Pelvic Organ Prolapse Impact Questionnaire (POPIQ-7), the Colorectal-Anal Impact
131 Questionnaire (CRAIQ-7), and the Urinary Impact Questionnaire (UIQ-7). Response options
132 range from 0 (“not at all”) to 3 (“quite a bit”). In each scale, the mean score of answered items is
133 multiplied by 33.3 to obtain the scale score (range 0–100). Summary scores are calculated by
134 adding up the scale scores (range 0–300). Higher scores indicate more impact on daily activity
135 (13, 14).

136 The POP-SS has seven items that focus on symptoms caused or aggravated by prolapse (26).
137 Each question requires participants to rate the frequency of symptom experienced in the four
138 weeks prior to evaluation. Symptom responses were rated on a 5-point Likert scale (0 = never, 1
139 = somewhat, 2 = sometimes, 3 = most of the time, and 4 = always). The total score ranged from
140 0 to 28. The total score was calculated by summing scores for individual symptom responses
141 (26). In this study the Amharic version was used and the detail was found elsewhere (20).

142 **Linguistic Translation and adaptation to Amharic language**

143 We followed multistep translation method (27) including forward translation, discussion with
144 translators, back-ward translation, expert discussion, and cognitive test on purposively selected
145 patients. First, to ensure semantic equivalence, the English versions were independently
146 translated into Amharic by two native experts who are fluent in the English-language, one of
147 them was familiar with the study subject. These two translated versions were reviewed by the
148 members of the researchers to create an initial Amharic versions. Next, the initial Amharic
149 versions were then back-translated into English by two independent native English speakers
150 (they are from the University of Gondar English language department) fluent in Amharic who
151 were blinded and naïve to the English versions. Thirdly, a one-day session was held to examine
152 the forward-and-back-translated versions with the original versions by urogynecologists,
153 urologist, a colorectal surgeon, and a psychometrician. Experts evaluate whether instruments
154 were equivalent in grammar, meaning, concept, and quality of the overall translation. They
155 examine all of the proceeding steps and selected the most appropriate translation for each item or
156 provided alternate translations. The overall discussion and meeting with experts were led by the
157 primary investigator (TB). At this stage, minor inconsistencies between the original and the
158 translated versions were resolved. Finally, to determine the readability of the language used,
159 cultural context, and to ask for their feedback on the comprehensiveness of items cognitive
160 debriefing was conducted with a convenience sample of ten native Amharic-speaking women
161 with and/or without PFDs visiting the gynecology clinic of the University of Gondar
162 Comprehensive and Specialized Hospital (UoGCSH). During cognitive debriefing, women were
163 asked to say something on the overall comprehensiveness of the tool, and some modifications in
164 some words were done. Minor problems were identified without the need to adapt the content of

165 the questionnaires. After the amendment of minor discrepancies, the Amharic versions were then
166 finalized for the evaluation of the psychometric properties of the scales.

167 **Psychometric Evaluation**

168 A cross-sectional study was conducted to examine the psychometric properties of the Amharic
169 versions of the PFDI-20 and PFIQ-7 between November 2020 and August 2021. Women with
170 and without POP were recruited from the gynecology outpatient clinics of the UoGCSH. Women
171 who had a psychiatric problem/cognitive impairment, could not speak or understand Amharic,
172 had undergone previous pelvic and/or anti-incontinence surgery within 6 months preceding the
173 study, had a known or suspected current pregnancy, were postpartum (the first 6 weeks following
174 childbirth) or <18 years of age were excluded.

175 The sample size was determined based on the recommendations of at least 5 subjects per item by
176 the Consensus-based Standards for the Selection of Health Measurement Instruments (COSMIN)
177 (28). To this end, the estimated sample was 205. But we included 10 participants to protect
178 against dropout and missing responses. Then the final participants we approached were 215.

179 The participants completed the paper form of the Amharic versions of PFDI-20 and PFIQ-7 at
180 baseline, and a randomly selected subsample ($n = 57$) completed the same instruments two
181 weeks later. This follow-up assessment was performed with face-to-face interviews by the same
182 data collectors who collected the baseline. After completing the instruments at baseline, all
183 participants underwent a gynecological examination in the dorsolithotomy position and the
184 prolapse stage was classified using the Pelvic Organ Prolapse Quantification System (POP-Q)
185 (29) by the research team members who were blinded to the questionnaires score of the
186 particular patient. Accordingly, women were assigned to stage 0 with no prolapse. Stage I,
187 leading point of the wall of the vagina or cervix remains at least 1 cm above the hymenal ring.
188 Stage II, leading point descends to the introitus, defined as an area extending from 1 cm above to
189 1 cm below the hymenal ring. The leading point descends >1 cm outside the hymenal ring in
190 stage III. However, it does not form a complete vaginal vault eversion or procidentia uteri. Stage
191 IV, complete vaginal vault eversion or procidentia uteri (29). Moreover, the definitions of the
192 International Continence Society were used to describe the clinical symptoms associated with
193 PFDs (30, 31). Thus, a woman was considered to have UI if the following conditions were

194 confirmed. Stress urinary incontinence (SUI): when there was involuntary leakage of urine on
195 activities like effort or exertion, or sneezing or coughing; urge incontinence (UUI): when there
196 was involuntary leakage that goes along with or immediately preceded by urgency; and mixed
197 urinary incontinence (MUI): when there was involuntary leakage of urine associated with both
198 urgency and stress UI. AI was defined by self-report of gas, stool, both gas and stool. FI was
199 defined as at least one symptom of incontinence of flatus or stool (only flatus, only loose stool,
200 only normal stool, or the combination of flatus, loose, and normal stool) (30, 31).

201 **Statistical analysis**

202 All statistical analyses were performed using SPSS for Windows 20.0 (SPSS Inc., Chicago, IL,
203 USA). A P-value of <0.05 was considered statistically significant. Participants' demographic and
204 clinical characteristics were summarized using descriptive statistics (percentages, frequencies,
205 means, and standard deviations). Normality was assessed for the outcome variables using the
206 Shapiro-Wilk test. The COSMIN recommendations were used for evaluating the psychometric
207 properties. Methodological testing, including reliability and validity was assessed (28).

208 Reliability was evaluated using internal consistency and test-retest reliability. Cronbach's alpha
209 was calculated to determine the internal consistency of subscale (correlation between the items
210 within a subscale) and summary (overall correlation between the items within a scale) scores in
211 the PFDI-20 and PFIQ-7 questionnaires, and values above 0.7 were considered adequate (28).
212 Test-retest reliability, the degree to which a measurement is free of error, was computed using
213 the interclass correlation coefficients (ICC) over a two-week interval (32). Women were asked if
214 their condition had changed during the interim period to evaluate their stability using the
215 question: 'Compared to the first time you completed the questionnaires, has your PFD condition
216 changed?' (If 'Yes', women were excluded from the retest). We assumed there would be no real
217 change in a women's level of function within two-week intervals. Good values of test-retest
218 reliability were considered greater than 0.70 (28).

219 Validity was evaluated using content, criterion and construct validity. Content validity, whether
220 the questionnaires could be understood and all the important and relevant items had been
221 included, was assessed by an expert panel and cognitive debriefing interviews during the
222 translation process. Expert agreement on relevance of each item was calculated using the Content

223 Validity Index (CVI) and agreement above 80% was considered acceptable (33). Moreover, we
224 calculated the floor and ceiling effects. We considered problematic if more than 15% of
225 participants achieved the highest or lowest possible score (28).

226 Criterion validity, which describes how well the questionnaire correlates with an existing gold
227 standard, was evaluated by comparing a relative criterion standard, the POP-SS-7 score, with
228 total PFDI-20 and subscale POPDI-6 scores using Spearman's correlation coefficient (SCC). The
229 SCC was defined as 0.8–1.0 excellent, 0.61–0.80 very good, 0.41–0.60 good, 0.21–0.40
230 sufficient, and 0.00–0.20 poor (34).

231 Construct validity was evaluated by known group validity and hypothesis testing. For known
232 group validity, patients were categorized into two groups: With POP (POP-Q score > 2) and
233 without POP, With UI and without UI, With AI and without AI. We hypothesized that PFDI-20
234 and PFIQ-7 scores are correlated with POP-Q scores, and patients with higher scores of POP-Q
235 had bothersome symptoms (PFDI) and poor quality of life (PFIQ). Moreover, patients with POP
236 would have higher POPDI-6 scores than those without these symptoms. Patients with UI had
237 higher UDI-6 scores than those without those symptoms. Summary and subscale PFDI-20 and
238 PFIQ-7 scores of these groups were tested using the Mann-Whitney U test since these scores did
239 not follow a normal distribution. Construct validity was considered adequate when at least 75 %
240 of these hypotheses were confirmed (28).

241 To evaluate the PFDI-20 and PFIQ-7 Amharic version's feasibility, the percentage of
242 unanswered individual items and the percentage of patients who did not answer any of the items
243 were analyzed. Also, the average administration time was calculated.

244

245

246

247

248

249

250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274

Results

Characteristics of participants

Of 234 consecutive women, 215 (91.9%) were eligible for inclusion of which 197 (91.6%) consented to participate at baseline. Women’s average age was 44.6 ± 13.6 years and the mean parity was 5.1 ± 3.3 .

Among those 197 participants at baseline, 117 (59.4%) were diagnosed with POP and 96 (48.8%) with POP-Q stage III and IV. Eighty had no symptoms of PFDs. Among women with POP, 63 had symptoms of UI and 36 had AI. Of the 63 women with UI, 36 had SUI, 23 had UUI, and the remaining two had mixed UI. Among the 36 women with AI, 21 had flatulence only, 12 had FI only, and the remaining three had both. The characteristics of the study participants are presented in **Table 1**.

At baseline, mean scores of the total PFDI-20 and PFIQ-7 were 116.4 ± 48.4 and 92.2 ± 34.2 , respectively, in women with PFDs. Similarly, in women without PFDs, mean scores were 2.2 ± 3.6 and 1.6 ± 2.3 for the PFDI-20 and PFIQ-7, respectively (**Table 2**).

275

276

277

278 Table 1: Characteristics of study participants, University of Gondar, Ethiopia (n = 197)

279

Characteristic	Statistics
Age (years) Mean \pm SD	44.6 \pm 13.6
Parity Mean \pm SD	5.1 \pm 3.3
Mode of delivery, n (%)	
Instrument	4 (2.2)
Vaginal	145 (80.6)
CS	15 (8.3)
Both vaginal and CS	7 (3.9)
POP-Q findings, n (%)	
Stage 0	80 (40.6)
Stage I	5 (2.5)
Stage II	16 (8.1)
Stage III	60 (30.5)
Stage IV	36 (18.3)
Urinary incontinence, n (%)	
SUI	38 (19.3)
UII	23 (11.7)
MUI	2 (1.0)
Anal incontinence, n (%)	
Fecal	12 (6.1)
Flatulence	21 (10.7)
Fecal and flatulence	3 (1.5)

280

281 *SD* standard deviation, *CS* cesarean section *POP-Q* Pelvic Organ Prolapse Quantification, *SUI*

282 stress urinary incontinence, *UII* urge urinary incontinence, *MUI* mixed urinary incontinence

283

284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315

Table 2: Pelvic Floor Distress Inventory–20 and Pelvic Floor Impact Questionnaire-7 scale and summary scores at baseline, University of Gondar, Ethiopia. (n = 197)

Characteristic	With PFD (n = 117)	Without PFD (n = 80)
PFDI-20	116.4 ± 48.4	2.2 ± 3.6
POPDI-6	53.1 ± 22.2	2.9 ± 4.6
CRADI-8	18.4 ± 12.8	1.1 ± 2.3
UDI-6	40.2 ± 25.0	2.2 ± 4.5
PFIQ-7	92.2 ± 34.2	1.6 ± 2.3
UIQ-7	47.6 ± 23.4	1.1 ± 2.8
CRAIQ-7	10.5 ± 7.2	1.2 ± 2.1
POPIQ-7	60.6 ± 24.2	1.1 ± 1.9

PFDI-20 Pelvic Floor Distress Inventory–Short Form 20, *POPDI* Pelvic Organ Prolapse Distress Inventory, *CRADI* Colorectal–Anal Distress Inventory, *UDI* Urinary Distress Inventory, *PFIQ-7* Pelvic Floor Impact Questionnaire-7, *UIQ* Urinary Impact Questionnaire, *CRAIQ* Colorectal–Anal Impact Questionnaire, *POPIQ* Pelvic Organ Prolapse Impact Questionnaire.

316

317

318

319 **Translation of the questionnaires**

320 Both forward-and-backward translation were performed as planned and no major problem was
321 encountered. The revisions made by the experts and women in the pilot study guaranteed the
322 content validity of the Amharic versions of the PFDI-20 and PFIQ-7. In the pilot study, most of
323 the items were well understood by the participating women. No words or items showed difficulty
324 in their comprehensibility and did not need to be adapted.

325 The final versions of the Amharic PFDI-20 and PFIQ-7 maintain the structure of the original
326 versions. The Amharic versions of PFDI-20 and PFIQ-7 are available upon request.

327 **Evaluation of measurement properties**

328 **Feasibility**

329 Concerning feasibility, all women responded to all items in the Amharic PFDI-20 and PFIQ-7
330 versions, and no missing items were found. Data collectors reported no difficulties in asking the
331 items and no women reported having met problems in understanding the items. The average time
332 for questionnaire administration was 9.4 min for PFDI-20 and 7.2 min for PFIQ-7.

333 **Reliability**

334 Internal consistency and test-retest reproducibility are shown in Table 3. Cronbach's alpha
335 coefficient values obtained from the Amharic versions of the PFDI-20 and PFIQ-7 total scores
336 were 0.92 (95% CI: 0.91, 0.94) and 0.91 (95% CI: 0.88, 0.92), respectively, demonstrating
337 excellent internal consistency. Similarly, their subscale coefficients also showed excellent
338 internal consistency, with values varying from 0.84 to 0.95 (**Table 3**).

339 To assess test-retest reliability, 57 women were reinterviewed two-weeks later. Seven women
340 reported a change in POP severity and were removed from the test-retest analysis, and 50 women
341 completed this test-retest correctly. As shown in Table 3, the test-retest reliability was excellent
342 between the paired scores of the total and subscale scores of PFDI-20 and PFIQ-7. The ICC was

343 0.97 in the PFDI-20 total score, and a range from 0.95 to 0.96 was found for its subscales.
 344 Moreover, the total PFIQ-7 score showed an ICC of 0.86, and its subscales varied from 0.87 to
 345 0.94. In both cases, all the ICCs were statistically significant ($p < 0.001$) (**Table 3**).

346
 347 Table 3: Reliability of the Amharic versions of the PFDI-20 and PFIQ-7 questionnaires

	Test–retest Reliability (n = 50)		Internal consistency (n = 197)
	ICC	P value ^a	Cronbach’s Alpha
PFDI-20	0.97	<0.001	0.92
POPDI-6	0.96	<0.001	0.88
CRADI-8	0.95	<0.001	0.84
UDI-6	0.96	<0.001	0.91
PFIQ-7	0.86	<0.001	0.91
UIQ-7	0.90	<0.001	0.93
CRAIQ-7	0.87	<0.001	0.95
POPIQ-7	0.94	<0.001	0.93

348 *ICC* Intraclass Correlation. *PFDI-20* Pelvic Floor Distress Inventory–Short Form 20, *POPDI*
 349 Pelvic Organ Prolapse Distress Inventory, *CRADI* Colorectal–Anal Distress Inventory, *UDI*
 350 Urinary Distress Inventory, *PFIQ-7* Pelvic Floor Impact Questionnaire-7, *UIQ* Urinary Impact
 351 Questionnaire, *CRAIQ* Colorectal–Anal Impact Questionnaire, *POPIQ* Pelvic Organ Prolapse
 352 Impact Questionnaire

353 ^a Single rating, absolute agreement, and a two-way mixed-effects model.

354
 355
 356
 357
 358
 359

360

361

362 **Content validity**

363 Content validity was established through expert committee review during the process of
364 adaptation and qualitative analysis of women's comments during a pilot study. The
365 multidisciplinary expert panel (urogynecologists, urologist, colorectal surgeon, physiotherapist,
366 and a psychometrician) agreed that the questionnaires included all the relevant items, and no
367 questions were added to the original versions. The mean scale value of the CVI for the PFDI-20
368 was 0.90 and for the PFIQ-7 was 0.92, which was above the cut-off of 0.80. The interviewed
369 women indicated that all items were well understood, and that the questionnaires showed good
370 readability and comprehensibility.

371 **Floor effect and ceiling effect**

372 No ceiling effects were observed in either group on the PFDI-20 and PFIQ-7 summary and
373 subscale scores. However, a floor effect was seen in both scales and subscales from both
374 instruments, with minimum frequency varying from 29.4% to 39.1% on PFDI-20 and 26.9% to
375 40.6% on PFIQ-7. In women with PFD, a floor effect was seen on the PFDI-20 (29.9%) and
376 PFIQ-7 scores (Data not shown).

377 **Criterion validity**

378 The Spearman correlation coefficient between the subscale POPDI-6 score and the POP-SS-7 in
379 the Amharic version was $r_s = 0.71$, $p < 0.001$, demonstrating very good criterion validity for
380 POPDI-6. Moreover, the SCC between the summary PFDI-20 and the POP-SS-7 score was
381 $r_s = 0.67$, $p < 0.001$, which proved that the POP-SS-7 score was significantly correlated with
382 the POPDI-6 score (Data not shown).

383 **Construct validity: Known groups**

384 There were statistically significant differences among the two groups of PFDs in the PFDI-20
385 and PFIQ-7 scores (Mann-Whitney U Test; $p < 0.001$). Women with POP had significantly

386 higher total and subscale scores on PFDI-20 and PFIQ-7 compared to non-prolapse women ($p <$
387 0.001), especially in the POPDI-6 (116.4 ± 48.4 vs 2.2 ± 3.6 ; $p < 0.001$) and POPIQ-7 ($60.6 \pm$
388 24.2 vs 1.1 ± 1.9 ; $p < 0.001$). Likewise, total PFDI-20, PFIQ-7, and all subscales scores were
389 higher in women with than without UI and AI ($p < 0.001$). The mean scores of the PFDI-20 and
390 PFIQ-7 scales by PFDs are shown in **Table 4**.

391 The analysis of SCC confirmed that both summary and subscale of the PFDI-20 and PFIQ-7
392 scores were correlated with the POP-Q vaginal examination findings (SCC Test; $p < 0.001$, data
393 not shown). The POP-Q significantly correlated with PFDI-20 score (SCC = 0.69; $P < 0.001$)
394 and with PFIQ-7 score (SCC = 0.71; $P < 0.001$). Furthermore, the PFIQ-7 score was significantly
395 correlated with PFDI-20 score (SCC = 0.79; $P < 0.001$). The higher SCC were related to POP
396 dimensions, either in PFDI-20 (POPDI = 0.73) and PFIQ-7 (POPIQ = 0.72).

397 All predefined hypotheses were confirmed, as shown in **Table 4** and criterion validity. Women
398 with POP reported higher scores on the POPDI-6 (116.4 ± 48.4) and POIQ-7 (60.6 ± 24.2) scales
399 than the non-prolapse women (2.2 ± 3.6 and 1.1 ± 1.9 , respectively, $p < 0.001$, **Table 4**).
400 Similarly women with UI and FI reported higher scores on subscale PFDI-20 score (UDI-6:
401 33.9 ± 24.9 vs 20.5 ± 26.9 and CRADI- 819.4 ± 12.9 vs 9.5 ± 12.5) and PFIQ-7 score (UIQ-7:
402 42.9 ± 28.4 vs 5.3 ± 6.6 and CRAIQ-7: 9.5 ± 7.5 vs 6.1 ± 37.1) than their counterparts, respectively
403 (**Table 4**). Moreover, PFDI-20 and PFIQ-7 scores are correlated with POP-Q scores (criterion
404 validity).

405

406

407

408

409

410

411

412

413

414 Table 4: Comparison of total and subscale PFDI-20 and PFIQ-7 scores between women with and
415 without PFDs (Known-groups validity)

416

417

Number	POP			UI			AI		
	Yes	No	P value*	Yes	No	P value*	Yes	No	P value*
	117	80		63	134		36	161	
PFDI-20	116.4±48.4	2.2±3.6	<0.001	101.4±55.1	55.2±67.9	<0.001	113.2±52.5	60.3±66.8	<0.001
POPDI-6	53.1±22.2	2.9±4.6	<0.001	46.6±24.1	26.2±30.6	<0.001	49.4±20.1	28.9±30.8	<0.001
CRADI-8	18.4±12.8	1.1±2.3	<0.001	16.3±13.7	9.1±12.2	<0.001	19.4±12.9	9.5±12.5	<0.001
UDI-6	40.2±25.0	2.2±4.5	<0.001	33.9±24.9	20.5±26.9	<0.001	43.8±24.1	20.5±28.1	<0.001
PFIQ-7	92.2±34.2	1.6±2.3	<0.001	88.1±46.3	22.0±27.3	<0.001	95.1±40.4	46.5±49.9	<0.001
UIQ-7	47.6±23.4	1.1±2.8	<0.001	42.9±28.4	5.3±6.6	<0.001	49.8±25.0	23.9±28.1	<0.001
CRAIQ-7	10.5±7.2	1.2±2.1	<0.001	29.7±17.9	27.6±33.6	<0.001	9.5±7.5	6.1±37.1	<0.001
POPIQ-7	60.6±24.2	1.1±1.9	<0.001	55.2±29.4	40.0±47.0	<0.001	61.0±25.7	30.9±34.2	<0.001

418

419 *PFDs* pelvic floor disorders, *POP* pelvic organ prolapse, *UI* urinary incontinence, *AI* anal
420 incontinence, *PFDI-20* Pelvic Floor Distress Inventory–Short Form 20, *POPDI* Pelvic Organ
421 Prolapse Distress Inventory, *CRADI* Colorectal–Anal Distress Inventory, *UDI* Urinary Distress
422 Inventory, *PFIQ-7* Pelvic Floor Impact Questionnaire-7, *UIQ* Urinary Impact Questionnaire,
423 *CRAIQ* Colorectal–Anal Impact Questionnaire, *POPIQ* Pelvic Organ Prolapse Impact
424 Questionnaire, Mean ± standard deviation

425 *Mann–Whitney U test

426

427

428

429

430

431

432

433

434 **Discussion**

435 PFDI-20 and PFIQ-7 have proven to be valid and reliable instruments to assess PFDs symptom
436 distress and measure their impact on women’s HRQoL (13, 14). Until now, their Amharic
437 translations have not been validated. In this study, we evaluated the reliability and validity of the
438 Amharic versions of the PFDI-20 and PFIQ-7. Both instruments were successfully translated and
439 culturally adapted. The results showed excellent internal consistency and test–retest reliability,
440 acceptable construct and very good criterion validity. All assumptions were confirmed. Thus, the
441 translated versions can be used as a standard tool in clinics and research in Amharic-speaking
442 women with PFDs.

443 It is essential to validate the instrument in a new population and language before its use (25, 35).
444 And the validation requires several steps, including linguistic, cultural, and psychometric
445 validation (25, 27). In the present study, the linguistic translation and cultural adaptation were
446 performed using a systematic approach. Since direct word-for-word translation does not
447 guarantee sufficient equivalence, emphasis was given to maintaining the original context and
448 meaning of the words of the questionnaires. Back-translation by two translators with different
449 backgrounds was performed in consideration of the differences in medical terminology and
450 subtle nuances. There were no changes in the instructions; and lay-out of the questionnaires.
451 Moreover, the format of the instruments was the same as the original scale ensuring technical
452 equivalence. Translations were similar to previous adaptations to Tigrigna, Swedish, Turkish and
453 Spanish (16, 17, 19). Content validity was determined in a similar way as described by previous
454 validation studies (16, 17, 19). Accordingly, we found that the instruments are content valid.
455 This was evidenced by excellent expert panel agreement on the relevance of items, being
456 reviewed by multilingual expert translators, and acceptance of the instruments during pre-testing.

457 The absence of difficulty in responding to the majority of items and the ease of completion
458 within a short period partly provides evidence for the acceptability of the Amharic versions in
459 the region in which the study was conducted. The time for completion in the present study was

460 comparable to the Spanish, Swedish and French validations (17, 36, 37). The average time of
461 filling in was 9 min for the PFDI-20 Amharic version, very similar to the French (9.2 min) and
462 Spanish (10.1 min) versions (36, 37). Regarding the PFIQ-7 Amharic version, it was 7.0 min,
463 higher than the French version (3.4 min), but similar to Spanish version (7.5 min) (36, 37).

464 This study establishes the reliability of Amharic versions of the PFDI-20 and PFIQ-7
465 questionnaires, as predicted. Both summary and subscale scores of the translated versions
466 showed excellent internal consistency with Cronbach's alpha between 0.84 and 0.95. The same
467 or very similar alphas were found in the Tigrigna (19), Polish (38), Greek (18), and Finnish (39)
468 versions. The two-week test-retest reliability also demonstrated an excellent correlation between
469 the paired test-retest scores of PFDI-20 (ICC of 0.97 in the PFDI-20 total score, and a range from
470 0.95 to 0.96 for its subscales) and PFIQ-7 (ICC of 0.86 for summary PFIQ-7 score and a range
471 from 0.87 to 0.94 for subscales; $p < 0.001$). Our findings were higher compared with a previous
472 study of Tigrigna (19), Polish (38), Greek (18), Finnish (39), and Norwegian (15) women. The
473 good test-retest reliability guaranteed that the questionnaire results were consistent over time.

474 Although no gold standard for PFD symptoms, the correlation between PFDI-20 and POPDI-6,
475 and POP-SS-7 were used to estimate criterion validity indirectly. The criterion validity was
476 found to be within an acceptable range. These findings are consistent with those of previous
477 studies [9, 13], although they used different relative standard as a criterion.

478 The current study also verified good construct validity, showing significant correlation between
479 PFDI-20 and PFIQ-7 and objective vaginal examination findings. The result is similar to some
480 validation studies (15, 40, 41). The PFDI-20 and PFIQ-7 scores increased as the POP-Q
481 increased. As most women with POP in our study were stage III or IV, PFDI-20 and PFIQ-7
482 total and subscale scores were higher than in other studies (40, 42, 43). The possible reason for
483 this might be population in our study was from rural areas and primarily uneducated, with
484 significant barriers to accessing care, resulting in longstanding prolapse and influencing
485 symptoms bother.

486 The strength of this study were the adoption of a multistep translation method, as supported by
487 existing evidence, rather than the simple translation-back-translation process (25, 27). However,
488 some limitations must be considered when interpreting the results of our study. First, our study
489 was conducted in an urban, single hospital; therefore, the results may not be generalizable to

490 populations in rural and remote areas. Further validation studies in more general contexts are
491 therefore recommended. Second, conducting a survey with self-report measures entails potential
492 bias due to socially desirable responses. Specifically, rates of illiteracy may impact the validity
493 (bias). Future studies should aim to utilize other methodologies that would enable a more in-
494 depth analysis. Third, responsiveness to change was not evaluated. Since the ability to detect a
495 change in prolapse symptoms due to an intervention is an important scale property, we
496 recommend the inclusion of this in future studies. Fourth, it was not possible to compare
497 construct validity with other generic questionnaires used for PFD evaluation, for example, the
498 Short Form Health Survey (SF-12) and International Consultation on Incontinence Questionnaire
499 Short Form (ICIQ-SF). This is because of the absence of translated and validated versions in
500 Amharic.

501 **Conclusion**

502 The Amharic versions of PFDI-20 and PFIQ-7 achieved good semantic, conceptual, idiomatic
503 and content equivalence with the original versions. The translated Amharic versions of the PFDI-
504 20 and PFIQ-7 are reliable, valid and feasible to measure symptoms and their impact on HRQoL
505 in Ethiopian Amharic-speaking women with PFDs. The questionnaires can be easily
506 administered and used in research and clinical settings. The Amhara Regional Health Bureau
507 should consider integrating these questionnaires into service delivery in the region. However,
508 prior piloting and modification for wider applicability, especially outside the study area is
509 needed. Further studies are also needed to evaluate the responsiveness of PFDI-20 and PFIQ-7.

510

511

512

513

514

515

516

517

518

519 **References**

- 520 1. Haylen BT, Maher CF, Barber MD, Camargo S, Dandolu V, Digesu A, et al. An International
521 Urogynecological Association (IUGA) / International Continence Society (ICS) Joint Report on the
522 Terminology for Female Pelvic Organ Prolapse (POP). *Neurourol Urodyn*. 2016;35(2):137-68.
- 523 2. Dieter AA, Wilkins MF, Wu JM. Epidemiological trends and future care needs for pelvic floor
524 disorders. *Current opinion in obstetrics & gynecology*. 2015;27(5):380.
- 525 3. Islam RM, Oldroyd J, Rana J, Romero L, Karim MN. Prevalence of symptomatic pelvic floor
526 disorders in community-dwelling women in low and middle-income countries: a systematic review and
527 meta-analysis. *International urogynecology journal*. 2019:1-11.
- 528 4. Gjerde JL, Rortveit G, Muleta M, Adefris M, Blystad A. Living with pelvic organ prolapse: voices of
529 women from Amhara region, Ethiopia. *Int Urogynecol J*. 2016.
- 530 5. Dheresa M, Worku A, Oljira L, Mengiste B, Assefa N, Berhane Y. One in five women suffer from
531 pelvic floor disorders in Kersa district Eastern Ethiopia: a community-based study. *BMC women's health*.
532 2018;18(1):95.
- 533 6. Doaee M, Moradi-Lakeh M, Nourmohammadi A, Razavi-Ratki SK, Nojomi M. Management of
534 pelvic organ prolapse and quality of life: a systematic review and meta-analysis. *Int Urogynecol J*.
535 2014;25(2):153-63.
- 536 7. Laganà AS, La Rosa VL, Rapisarda AMC, Vitale SG. Pelvic organ prolapse: the impact on quality of
537 life and psychological well-being. *Journal of Psychosomatic Obstetrics & Gynecology*. 2018;39(2):164-6.
- 538 8. Magowan BA, Owen P, Thomson A. *Clinical obstetrics and gynaecology E-Book: Elsevier Health*
539 *Sciences*; 2014.
- 540 9. Touza KK, Rand KL, Carpenter JS, Chen CX, Heit MH. A scoping study of psychosocial factors in
541 women diagnosed with and/or treated for pelvic organ prolapse. *life (QOL)*. 2018;4(9):10.
- 542 10. Baessler K, O'Neill SM, Maher CF, Battistutta D. A validated self-administered female pelvic floor
543 questionnaire. *International urogynecology journal*. 2010;21(2):163-72.
- 544 11. Calvert M, Brundage M, Jacobsen PB, Schünemann HJ, Efficace FJH, outcomes qol. The
545 CONSORT Patient-Reported Outcome (PRO) extension: implications for clinical trials and practice.
546 2013;11(1):1-7.
- 547 12. Gutman RE, Ford DE, Quiroz LH, Shippey SH, Handa VL. Is there a pelvic organ prolapse
548 threshold that predicts pelvic floor symptoms? *Am J Obstet Gynecol*. 2008;199(6):683 e1-7.
- 549 13. Rogers RG, Coates KW, Kammerer-Doak D, Khalsa S, Qualls C. A short form of the Pelvic Organ
550 Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12). *Int Urogynecol J Pelvic Floor Dysfunct*.
551 2003;14(3):164-8; discussion 8.
- 552 14. Barber MD, Walters MD, Bump RC. Short forms of two condition-specific quality-of-life
553 questionnaires for women with pelvic floor disorders (PFDI-20 and PFIQ-7). *Am J Obstet Gynecol*.
554 2005;193(1):103-13.
- 555 15. Utomo E, Blok BF, Steensma AB, Korlage IJ. Validation of the Pelvic Floor Distress Inventory
556 (PFDI-20) and Pelvic Floor Impact Questionnaire (PFIQ-7) in a Dutch population. *Int Urogynecol J*.
557 2014;25(4):531-44.

- 558 16. Kaplan PB, Sut N, Sut HK. Validation, cultural adaptation and responsiveness of two pelvic-floor-
559 specific quality-of-life questionnaires, PFDI-20 and PFIQ-7, in a Turkish population. *Eur J Obstet Gynecol*
560 *Reprod Biol.* 2012;162(2):229-33.
- 561 17. Telemann P, Stenzelius K, Iorizzo L, Jakobsson U. Validation of the Swedish short forms of the
562 Pelvic Floor Impact Questionnaire (PFIQ-7), Pelvic Floor Distress Inventory (PFDI-20) and Pelvic Organ
563 Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12). *Acta Obstet Gynecol Scand.*
564 2011;90(5):483-7.
- 565 18. Grigoriadis T, Athanasiou S, Giannoulis G, Mylonas S-C, Lourantou D, Antsaklis AJL. Translation
566 and psychometric evaluation of the Greek short forms of two condition-specific quality of life
567 questionnaires for women with pelvic floor disorders: PFDI-20 and PFIQ-7. 2013;24(12):2131-44.
- 568 19. Goba GK, Legesse AY, Zelelew YB, Gebreselassie MA, Rogers RG, Kenton KS, et al. Reliability and
569 validity of the Tigrigna version of the Pelvic Floor Distress Inventory–Short Form 20 (PFDI-20) and Pelvic
570 Floor Impact Questionnaire-7 (PFIQ-7). *International urogynecology journal.* 2019;30(1):65-70.
- 571 20. Belayneh T, Gebeyehu A, Adefris M, Rortveit G, Genet T. Validation of the Amharic version of
572 the Pelvic Organ Prolapse Symptom Score (POP-SS). *International urogynecology journal.* 2018:1-8.
- 573 21. Belayneh T, Gebeyehu A, Adefris M, Rortveit G, Genet T. Translation, transcultural adaptation,
574 reliability and validation of the pelvic organ prolapse quality of life (P-QoL) in Amharic. *Health and*
575 *quality of life outcomes.* 2019;17(1):12.
- 576 22. Gebremichael M. *Federalism and Conflict Management in Ethiopia. Case Study of Benishangul-*
577 *Gumuz Regional State.*: University of Bradford. <http://hdl.handle.net/10454/5388>; 2012.
- 578 23. Central SA. *The 2007 Population and Housing Census of Ethiopia: Statistical Report at Country*
579 *Level.* 2007. pp.91-92. Available at: <http://catalog.ihnsn.org/index.php/catalog/3583/download/50086>
580 [Accessed 16 September 2018]. 2010.
- 581 24. Uysal-Bozkir Ö, Parlevliet JL, de Rooij SE. Insufficient cross-cultural adaptations and
582 psychometric properties for many translated health assessment scales: A systematic review. *Journal of*
583 *clinical epidemiology.* 2013;66(6):608-18.
- 584 25. Acquadro C, Conway K, Hareendran A, Aaronson N. Literature review of methods to translate
585 health-related quality of life questionnaires for use in multinational clinical trials. *Value in Health.*
586 2008;11:509-21.
- 587 26. Hagen S, Glazener C, Sinclair L, Stark D, Bugge C. Psychometric properties of the pelvic organ
588 prolapse symptom score. *BJOG.* 2009;116(1):25-31.
- 589 27. Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural
590 adaptation of self-report measures. *Spine.* 2000;25:3186-91.
- 591 28. Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, et al. Quality criteria were
592 proposed for measurement properties of health status questionnaires. *Journal of clinical epidemiology.*
593 2007;60(1):34-42.
- 594 29. Manonai J, Mouritsen L, Palma P, Contreras-Ortiz O, Korte JE, Swift S. The inter-system
595 association between the simplified pelvic organ prolapse quantification system (S-POP) and the standard
596 pelvic organ prolapse quantification system (POPQ) in describing pelvic organ prolapse. *Int Urogynecol J.*
597 2011;22(3):347-52.
- 598 30. Haylen BT, De Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International
599 Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the
600 terminology for female pelvic floor dysfunction. *Neurourology and Urodynamics: Official Journal of the*
601 *International Continence Society.* 2010;29(1):4-20.
- 602 31. Lukacz ES, Lawrence JM, Buckwalter JG, Burchette RJ, Nager CW, Lubner KM. Epidemiology of
603 prolapse and incontinence questionnaire: validation of a new epidemiologic survey. *International*
604 *urogynecology journal.* 2005;16(4):272-84.

- 605 32. Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, et al. The COSMIN checklist
606 for assessing the methodological quality of studies on measurement properties of health status
607 measurement instruments: an international Delphi study. *Quality of life research*. 2010;19(4):539-49.
- 608 33. Polit DF, Beck CT. The content validity index: are you sure you know what's being reported?
609 Critique and recommendations. *Research in nursing & health*. 2006;29:489-97.
- 610 34. Streiner DL, Norman GR, Cairney J. *Health measurement scales: a practical guide to their*
611 *development and use*: Oxford University Press, USA; 2015.
- 612 35. Hagen S, Glazener C, Cook J, Herbison P, Toozs-Hobson P. Further properties of the pelvic organ
613 prolapse symptom score: minimally important change and test-retest reliability. *Neurourol Urodyn*.
614 2010;29:1055-6.
- 615 36. Sánchez-Sánchez B, Torres-Lacomba M, Yuste-Sánchez MJ, Navarro-Brazález B, Pacheco-da-
616 Costa S, Gutiérrez-Ortega C, et al. Cultural adaptation and validation of the pelvic floor distress inventory
617 short form (PFDI-20) and pelvic floor impact questionnaire short form (PFIQ-7) Spanish versions.
618 2013;170(1):281-5.
- 619 37. De Tayrac R, Deval B, Fernandez H, Mares PJJdG, *Obstetrique et Biologie de la Reproduction*.
620 Development of a linguistically validated French version of two short-form, condition-specific quality of
621 life questionnaires for women with pelvic floor disorders (PFDI-20 and PFIQ-7). 2007;36(8):738-48.
- 622 38. Bochenska K, Grzybowska ME, Piaskowska-Cala J, Mueller M, Lewicky-Gaup C, Wydra D, et al.
623 Translation and validation of the Polish version of the Pelvic Floor Impact Questionnaire short form 7.
624 2021;32(12):3177-81.
- 625 39. Mattsson NK, Nieminen K, Heikkinen A-M, Jalkanen J, Koivurova S, Eloranta M-L, et al. Validation
626 of the short forms of the pelvic floor distress inventory (PFDI-20), pelvic floor impact questionnaire
627 (PFIQ-7), and pelvic organ prolapse/urinary incontinence sexual questionnaire (PISQ-12) in Finnish.
628 2017;15(1):1-7.
- 629 40. Arouca MAF, Duarte TB, Lott DAM, Magnani PS, Nogueira AA, Rosa-e-Silva JC, et al. Validation
630 and cultural translation for Brazilian Portuguese version of the pelvic floor impact questionnaire (PFIQ-7)
631 and pelvic floor distress inventory (PFDI-20). 2016;27(7):1097-106.
- 632 41. Henn EW, Richter BW, Marokane MMJIUJ. Validation of the PFDI-20 and PFIQ-7 quality of life
633 questionnaires in two African languages. 2017;28(12):1883-90.
- 634 42. Ma Y, Xu T, Zhang Y, Mao M, Kang J, Zhu LJ. Validation of the Chinese version of the Pelvic
635 Floor Distress Inventory-20 (PFDI-20) according to the COSMIN checklist. 2019;30(7):1127-39.
- 636 43. Teig CJ, Grotle M, Bond MJ, Prinsen CA, Engh MAE, Cvancarova MS, et al. Norwegian translation,
637 and validation, of the pelvic floor distress inventory (PFDI-20) and the pelvic floor impact questionnaire
638 (PFIQ-7). 2017;28(7):1005-17.

639